Blepharitis

22
Pipeline Programs
5
Companies
9
Clinical Trials
16
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
1
17
Early DiscoveryClinical DevelopmentMarket

On Market (16)

Approved therapies currently available

U
A/T/SApproved
erythromycin
Unknown Company
topical1982
Bausch + Lomb
AKNE-MYCINApproved
erythromycin
Bausch + Lomb
topical1985
U
C-SOLVE-2Approved
erythromycin
Unknown Company
topical1993
U
E-GLADESApproved
erythromycin
Unknown Company
topical2002
U
E-SOLVE 2Approved
erythromycin
Unknown Company
topical1985
U
EMGELApproved
erythromycin
Unknown Company
topical1991
U
ERY-TABApproved
erythromycin
Unknown Company
Macrolide [EPC]oral1982
U
ERYTHRO-STATINApproved
erythromycin
Unknown Company
topical1996
U
ERYTHROMYCINApproved
erythromycin
Unknown Company
topical1982
U
ERYTHROMYCIN ETHYLSUCCINATEApproved
erythromycin
Unknown Company
oral2019
U
ILOTYCINApproved
erythromycin
Unknown Company
ophthalmic1964
U
R-P MYCINApproved
erythromycin
Unknown Company
oral
U
ROBIMYCINApproved
erythromycin
Unknown Company
oral
U
SANSACApproved
erythromycin
Unknown Company
topical1985
U
STATICINApproved
erythromycin
Unknown Company
topical1980
U
T-STATApproved
erythromycin
Unknown Company
topical1987

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
ErythromycinPhase 41 trial
Active Trials
NCT01478256Completed30Est. Oct 2011
Alcon
AlconFORT WORTH, TX
1 program
1
Moxifloxacin and Dexamethasone combinedPhase 31 trial
Active Trials
NCT00732446CompletedEst. Feb 2009
M&
Merck & Co.RAHWAY, NJ
3 programs
3
Azithromycin ophthalmic solution, 1%Phase 23 trials
Azithromycin ophthalmic solution, 1%Phase 21 trial
Azithromycin ophthalmic solution, 1%Phase 21 trial
Active Trials
NCT01220258Terminated29Est. Aug 2011
NCT01105624Completed50Est. Nov 2010
NCT00892970Completed313Est. Jan 2010
+2 more trials
Thea Pharma
Thea PharmaMA - Waltham
1 program
1
AzithromycinPhase 21 trial
Active Trials
NCT01089608CompletedEst. Jun 2012
Optima
OptimaGermany - Schwaebisch Hall
1 program
Group AN/A1 trial
Active Trials
NCT01115192Completed144Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch + LombErythromycin
Merck & Co.Azithromycin ophthalmic solution, 1%
AlconMoxifloxacin and Dexamethasone combined
Merck & Co.Azithromycin ophthalmic solution, 1%
Merck & Co.Azithromycin ophthalmic solution, 1%
Thea PharmaAzithromycin
Merck & Co.Azithromycin ophthalmic solution, 1%
Merck & Co.Azithromycin ophthalmic solution, 1%
OptimaGroup A

Clinical Trials (9)

Total enrollment: 920 patients across 9 trials

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

Start: Aug 2011Est. completion: Oct 201130 patients
Phase 4Completed
NCT01105624Merck & Co.Azithromycin ophthalmic solution, 1%

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

Start: Mar 2010Est. completion: Nov 201050 patients
Phase 4Completed
NCT00732446AlconMoxifloxacin and Dexamethasone combined

Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis

Start: Aug 2008Est. completion: Feb 2009
Phase 3Completed
NCT01269658Merck & Co.Azithromycin ophthalmic solution, 1%

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)

Start: Dec 2010Est. completion: Jun 201140 patients
Phase 2Terminated
NCT01220258Merck & Co.Azithromycin ophthalmic solution, 1%

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Start: Nov 2010Est. completion: Aug 201129 patients
Phase 2Terminated

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Start: Mar 2010Est. completion: Jun 2012
Phase 2Completed
NCT00894530Merck & Co.Azithromycin ophthalmic solution, 1%

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Start: May 2009Est. completion: Dec 2009314 patients
Phase 2Completed
NCT00892970Merck & Co.Azithromycin ophthalmic solution, 1%

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

Start: Apr 2009Est. completion: Jan 2010313 patients
Phase 2Completed

Blephacura Versus Baby Shampoo to Treat Blepharitis

Start: May 2010Est. completion: Dec 2010144 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space